These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 27884978)

  • 1. Oestrogen receptor negativity in breast cancer: a cause or consequence?
    Gajulapalli VNR; Malisetty VL; Chitta SK; Manavathi B
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27884978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
    Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
    Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
    Kondo N; Toyama T; Sugiura H; Fujii Y; Yamashita H
    Cancer Res; 2008 Jul; 68(13):5004-8. PubMed ID: 18593897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current research topics in endocrine therapy for breast cancer.
    Yamashita H
    Int J Clin Oncol; 2008 Oct; 13(5):380-3. PubMed ID: 18946747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
    Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
    PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives.
    Sukocheva OA; Lukina E; Friedemann M; Menschikowski M; Hagelgans A; Aliev G
    Semin Cancer Biol; 2022 Jul; 82():35-59. PubMed ID: 33301860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.
    Linares A; Assou S; Lapierre M; Thouennon E; Duraffourd C; Fromaget C; Boulahtouf A; Tian G; Ji J; Sahin O; Badia E; Boulle N; Cavaillès V
    Mol Oncol; 2019 Jul; 13(7):1534-1547. PubMed ID: 31099456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
    Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
    Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
    Chen XS; Wang KS; Guo W; Li LY; Yu P; Sun XY; Wang HY; Guan YD; Tao YG; Ding BN; Yin MZ; Ren XC; Zhang Y; Chen CS; Ye YC; Yang JM; Cheng Y
    Theranostics; 2020; 10(4):1833-1848. PubMed ID: 32042339
    [No Abstract]   [Full Text] [Related]  

  • 17. Endocrine resistance: what do we know?
    Miller TW
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
    Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
    Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
    Giessrigl B; Schmidt WM; Kalipciyan M; Jeitler M; Bilban M; Gollinger M; Krieger S; Jäger W; Mader RM; Krupitza G
    Br J Cancer; 2013 Nov; 109(10):2751-62. PubMed ID: 24169358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
    Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
    Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.